DURHAM, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) — Parexelone of the world’s largest clinical research organizations (CROs) providing the full spectrum of clinical development services from Phase I to IV, today announced that its near-term, science-based greenhouse gas (GHG) emission reduction targets have been validated by the Science Based Targets Initiative (SBTi). SBTi validation is a recognition widely considered the gold standard for setting and reducing corporate greenhouse gas emissions. The company is one of the few global CROs with validated, science-based targets.
SBTi has confirmed Parexel’s commitment to reduce absolute Scope 1 greenhouse gas emissions by 42% by 2030 (from the 2022 base year). The company’s commitment to continue to actively source 100% renewable electricity annually through 2030 and to reduce absolute Scope 3 greenhouse gas emissions by 25% by 2030 (from the 2022 base year) has also been confirmed.
“SBTi’s endorsement of our near-term goals is an important milestone on our journey to achieve net-zero greenhouse gas emissions,” said CEO Peyton Howell. “Our environmental approach is comprehensive and multifaceted, bringing together team members from across the Parexel group. Together, we are maximizing our industry partnerships and engaging our supply chain to collectively reduce the environmental impact of our operations and contribute to a healthier planet.”
As part of its net zero roadmap, Parexel is executing plans to meet its 2025 commitments, including increasing occupancy in green buildings, promoting sustainable travel options to reduce emissions, sourcing 100% of purchased electricity from renewable energy, and promoting green clinical trials. Parexel’s 2023 ESG report highlights the company’s ongoing efforts and reaffirms its core commitment to prioritizing patients and With Heart™.
About Parexel
Parexel is one of the world’s largest contract research organizations (CROs), providing the full spectrum of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Our team of more than 21,000 professionals worldwide leverage the breadth of our clinical, regulatory and therapeutic expertise and partner with leading biopharmaceutical companies, emerging innovators and sites to design and conduct clinical trials with patients in mind, improve access and participation, and make clinical research a treatment option for everyone, everywhere. Our deep industry knowledge and strong track record acquired over the past 40 years advances the industry and advances clinical research in the most complex areas of healthcare, while our innovation ecosystem provides quality solutions to make every phase of the clinical trial process more efficient. With the people, insight and focus on operational excellence we work With Heart™ every day to treat patients with dignity and continually learn from their experiences so that every trial makes a difference. This approach continues to earn us industry-wide recognition. Parexel was named “Best Contract Research Organization” by an independent panel for Citeline in November 2023, “Top CRO to Partner With” by investigational sites worldwide in the 2023 WCG CenterWatch Global Site Relationship Benchmark Survey, and received the 2023 Society for Clinical Research Sites (SCRS) Eagle Award for advancing the clinical research profession through strong site partnerships. For more information, visit parexel.com. Also follow us on LinkedIn, X, Facebook, and Instagram.
MEDIA
Lori Preuit Dorer
Parexel
+1 513 496 8121
[email protected]
Addison Stallings
Parexel
+1 984 833 6362
[email protected]
